---
layout: default
title: Avibactam
parent: 僅模型預測 (L5)
nav_order: 53
evidence_level: L5
indication_count: 6
---

# Avibactam
{: .fs-9 }

證據等級: **L5** | 預測適應症: **6** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Avibactam: Drug Repurposing Evaluation — No TxGNN Predictions Available

## One-Sentence Summary

Avibactam (DB09060) is a β-lactamase inhibitor typically used in combination antibiotic therapies for resistant gram-negative bacterial infections.
The TxGNN model has **not generated any predicted indications** for this compound in the current Evidence Pack,
and no supporting clinical trial or literature evidence is available for evaluation at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded in current dataset |
| Predicted New Indication | None |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| Finland Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The current Evidence Pack contains no TxGNN predicted indications for Avibactam, and critical foundational data — including mechanism of action, original approved indication, and safety warnings — are all absent. A repurposing evaluation cannot meaningfully proceed without these elements.

**To proceed, the following is needed:**

- **TxGNN predictions**: Run the prediction pipeline for Avibactam (DB09060) to generate candidate new indications
- **Mechanism of action (MOA)**: Retrieve from DrugBank API to enable mechanistic plausibility analysis
- **Safety data**: Download and parse the package insert PDF from TFDA official website to obtain warnings and contraindications
- **Original approved indication**: Confirm from TFDA or EMA/FDA regulatory sources
- **DDI data**: Query drug interaction database (current query returned no results)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

